Trial Profile
Inhibition of Delta-Protein Kinase C for the Reduction of Infarct Size in Acute Myocardial Infarction
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Oct 2021
Price :
$35
*
At a glance
- Drugs Delcasertib (Primary)
- Indications Myocardial infarction
- Focus Therapeutic Use
- Acronyms PROTECTION AMI
- Sponsors KAI Pharmaceuticals
- 01 Sep 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
- 01 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Apr 2011 Results presented as a late-breaking clinical trial in the proceedings of ACC 2011.